Pharma and healthcare: sector news on Thursday 29 October 2026
Average tone +1.2 (neutral) across 5 companies with relevant coverage, from 97 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| GSK | −6.3 | 77 | Coverage centred on third-quarter results, which beat estimates and kept 2026 guidance, with specialty medicines driving growth. |
| AstraZeneca | +2.8 | 13 | Coverage was mostly mildly positive, led by an EU approval for Enhertu, reports that the company is weighing a move into cancer vaccines and awareness and recognition stories. |
| Haleon | +5.7 | 5 | Coverage centred on the appointment of a new marketing and transformation lead and on commentary that the shares look undervalued given flu demand forecasts. |
| Convatec | +9.7 | 1 | Coverage centred on Convatec's plan to invest £500 million in a worldwide research and development centre in Manchester across the coming ten years. |
| Smith & Nephew | −5.8 | 1 |
Strongest stories in the sector
- −10.0 Shares fell on weaker sales and rising costs.
- −10.0 Shares fell on vaccines and restructuring charges.
- −10.0 Shares fell sharply as vaccine sales worried investors.
- +9.7 Large decade-long investment in a new research centre signals commitment to future product pipeline.
- −9.2 Shares slumped as vaccine sales declined.
- −9.2 Vaccine sales missed forecasts on weaker adult demand.
- −9.2 Vaccine and HIV stumbles erased prior share gains.
- −9.2 Shares fell after vaccine disappointment.
- −9.2 Shares hit by disappointing vaccine sales.
- −9.2 Shares dropped sharply on vaccine weakness and pipeline concerns.
- −8.3 Shares slumped on falling vaccine sales.
- −8.3 Shares slipped on weaker vaccine sales.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.